- Vivici has formed a partnership with Ginkgo to advance
production of a sustainable and nutritious dairy protein, made via
precision fermentation.
- Ginkgo will use its Protein Production Services
and generative AI platform to deliver best-in-class candidate
strains to Vivici.
- Vivici will use the strains from this collaboration to extend
their existing range of proteins, supporting innovative specialized
nutrition companies, to bring planet-friendly nutrition to
consumers.
DELFT, Netherlands and BOSTON, Nov. 27,
2023 /PRNewswire/ -- Vivici BV, an innovative
B2B ingredients startup company using precision fermentation to
make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA),
which is building the leading platform for cell programming and
biosecurity, today announced a new partnership. Through this
collaboration, Vivici will leverage Ginkgo's extensive capabilities
in strain engineering, optimization and performance, to develop and
commercialize a next generation of functional alternative
protein.
Alternative Dairy Protein Production with
Precision Fermentation
Vivici, a startup company founded by DSM Venturing (now part of
dsm-firmenich) and Fonterra, is on a mission to meet the world's
growing need for sustainable, nutritious and great tasting
proteins. Recognizing the need for alternatives to traditional
animal agriculture, Vivici employs precision fermentation
techniques to produce animal-free dairy proteins with
microorganisms. This innovative approach not only supplements the
existing animal protein supply, but also paves the way for a more
sustainable food system in the future.
Ginkgo's Tech Solution: Strain Development at
Foundry Scale
Ginkgo plans to support Vivici by delivering optimized strains
for dairy protein production via precision fermentation. Ginkgo
intends to design and build an integrated library, screen for
strains with the best protein expression, validate and grow the
most promising hits, and then transfer the top performing strains
to Vivici for evaluation. The aim is for these strains to enable
optimal protein expression, superior functionality, and
commercial-level titers.
"We are thrilled to collaborate with Ginkgo. Ginkgo's scale and
AI-driven approach to designing strains for protein expression is a
differentiated offering. We are confident in Ginkgo's capabilities
to provide efficient, scalable strains that can support Vivici's
speed to market," said Stephan van Sint
Fiet, CEO at Vivici.
"We're so excited to support Vivici in its vision of meeting
growing demand for animal-free protein alternatives. We're here to
help Vivici deliver on the promise that precision fermentation can
lead to planet-friendly nutrition," said Kevin Madden, Senior Vice President of
Commercialization at Ginkgo Bioworks. "We believe our speed and
experience with dairy protein development, ultra high throughput
screening, and fermentation scale-up can enable Vivici to
successfully expand their current protein portfolio and bring new
solutions to market. We're eager to help Vivici enter the market as
a provider of sustainable and nutritious animal-free protein
solutions to a wide range of customers."
About Ginkgo Bioworks
Ginkgo Bioworks is the leading
horizontal platform for cell programming, providing flexible,
end-to-end services that solve challenges for organizations across
diverse markets, from food and agriculture to pharmaceuticals to
industrial and specialty chemicals. Ginkgo's biosecurity and public
health unit, Concentric by Ginkgo, is building global
infrastructure for biosecurity to empower governments, communities,
and public health leaders to prevent, detect and respond to a wide
variety of biological threats. For more information,
visit ginkgobioworks.com and concentricbyginkgo.com, read
our blog, or follow us on social media channels such as X
(formerly known as Twitter) (@Ginkgo and @ConcentricByGBW),
Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads
(@GinkgoBioworks) or LinkedIn.
About Vivici
Vivici is an innovative Dutch B2B
ingredients company, supplying food and beverage brands with
nutritious and sustainable animal-free dairy proteins, made with
precision fermentation. Launching in early 2024, Vivici will bring
its first product to market, a nature-equivalent whey protein,
beta-lactoglobulin. As a B2B company Vivici will be supplying into
leading innovative food and beverage brands who are looking to
bring more sustainable whey offerings and improved animal-free
consumer products to market.
For more information visit www.vivici.com, contact us via
info@vivici.com or follow us through LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This
press release contains certain forward-looking statements within
the meaning of the federal securities laws, including statements
regarding the capabilities and potential success of the partnership
and Ginkgo's cell programming platform. These forward-looking
statements generally are identified by the words "believe," "can,"
"project," "potential," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result," and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) our ability to realize the
expected benefits of merger and acquisition transactions, (vii) the
outcome of any legal proceedings against Ginkgo, including as a
result of recent acquisitions, (viii) our ability to realize the
expected benefits from and the success of our Foundry platform
programs, (ix) our ability to successfully develop engineered
cells, bioprocesses, data packages or other deliverables, and (x)
the product development or commercialization success of our
customers. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors" section of
Ginkgo's quarterly report on Form 10-Q filed with the U.S.
Securities and Exchange Commission (the "SEC") on November 8, 2023 and other documents filed by
Ginkgo from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
VIVICI CONTACT:
Stephan van
Sint Fiet: stephan.vansintfiet@vivici.com
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vivici-selects-ginkgo-bioworks-to-extend-their-range-of-novel-dairy-proteins-301997511.html
SOURCE Ginkgo Bioworks